Key Stats for Merck Stock
- Price change for Merck stock in last 6 months: 24%
- $MRK Stock Price as of Aug. 19: $152
- 52-Week High: $154
- $MRK Stock Price Target: $138
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Merck (MRK) stock climbed more than 12% on Wednesday after Merck and Moderna announced strong results from their first-ever late-stage trial of a personalized cancer vaccine.
The shot, paired with Merck’s blockbuster immunotherapy Keytruda, hit its main goal in a Phase 3 study of over 1,100 melanoma patients who had already had their tumors surgically removed.
The combination significantly extended the time patients went without their melanoma coming back, compared to Keytruda alone. It also lowered the risk of the cancer spreading to other parts of the body. These results build on positive Phase 2 data the companies shared earlier this year.
Dr. Dean Li, president of Merck Research Laboratories, said the companies expect to start talking with regulators about the treatment “in the next few months.” Merck’s Dr. Jane Healy called the results “very exciting,” pointing out that the improvement over Keytruda alone was “clinically meaningful” and that patients tolerated the treatment well, with side effects similar to other common vaccines.
The vaccine takes a personalized approach.
Instead of a one-size-fits-all treatment, it targets the specific mutations found in each patient’s tumor.
It trains the immune system to recognize and destroy those unique markers, then pairs that response with Keytruda to help the body fight the cancer more effectively. Healy noted this validates an approach Merck and Moderna have spent decades developing.
See analysts’ growth forecasts and price targets for Merck stock (It’s free) >>>
What the Market Is Telling Us About Merck Stock
Merck stock’s 13% jump is a big move for a company this size, and it shows investors see real value in this data.
While the percentage gain looks smaller next to Moderna’s 177% surge, that difference mostly comes down to size. Merck entered the week worth around $333 billion, so a win like this adds real dollars even if the percentage move looks modest by comparison.
For Merck, this trial is one piece of a much bigger picture. The company is already generating strong growth from Keytruda and other newer products, and management has pointed to a large pipeline of new treatments they expect to drive growth for years.
A positive melanoma readout adds another potential growth driver, since Merck and Moderna are also testing the same vaccine in lung, bladder, and kidney cancers.
Melanoma makes up only about 1% of skin cancers but causes a large share of skin cancer deaths, so a new treatment option matters.
The market’s reaction suggests investors view this less as a one-off event and more as proof that Merck stock has real upside tied to its oncology pipeline beyond Keytruda alone.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Merck Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
